Literature DB >> 17018527

Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C.

Daniel M Dupont1, Grant E Blouse, Martin Hansen, Lisa Mathiasen, Signe Kjelgaard, Jan K Jensen, Anni Christensen, Ann Gils, Paul J Declerck, Peter A Andreasen, Troels Wind.   

Abstract

Latency transition of plasminogen activator inhibitor-1 (PAI-1) occurs spontaneously in the absence of proteases and results in stabilization of the molecule through insertion of its reactive center loop (RCL) as a strand in beta-sheet A and detachment of beta-strand 1C (s1C) at the C-terminal hinge of the RCL. This is one of the largest structural rearrangements known for a folded protein domain without a concomitant change in covalent structure. Yet, the sequence of conformational changes during latency transition remains largely unknown. We have now mapped the epitope for the monoclonal antibody H4B3 to the cleft revealed upon s1C detachment and shown that H4B3 inactivates recombinant PAI-1 in a time-dependent manner. With fluorescence spectroscopy, we show that insertion of the RCL is accelerated in the presence of H4B3, demonstrating that the loss of activity is the result of latency transition. Considering that the epitope for H4B3 appears to be occluded by s1C in active PAI-1, this finding suggests the existence of a pre-latent conformation on the path from active to latent PAI-1 characterized by at least partial detachment of s1C. Functional characterization of mutated PAI-1 variants suggests that a salt-bridge between Arg273 and Asp224 may stabilize the pre-latent conformation. The binding of H4B3 and of a peptide targeting the cleft revealed upon s1C detachment was hindered by the glycans attached to Asn267. Conclusively, we have provided evidence for the existence of an equilibrium between active PAI-1 and a pre-latent form, characterized by reversible detachment of s1C and formation of a glycan-shielded cleft in the molecule.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018527     DOI: 10.1074/jbc.M606851200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

2.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.

Authors:  Lawrence C Thompson; Sumit Goswami; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

3.  High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.

Authors:  Jan K Jensen; Peter G W Gettins
Journal:  Protein Sci       Date:  2008-08-25       Impact factor: 6.725

4.  Characterization of the conformational alterations, reduced anticoagulant activity, and enhanced antiangiogenic activity of prelatent antithrombin.

Authors:  Benjamin Richard; Richard Swanson; Sophia Schedin-Weiss; Ben Ramirez; Gonzalo Izaguirre; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2008-03-28       Impact factor: 5.157

5.  Serpin latency transition at atomic resolution.

Authors:  Giorgia Cazzolli; Fang Wang; Silvio a Beccara; Anne Gershenson; Pietro Faccioli; Patrick L Wintrode
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

6.  Structural factors affecting the choice between latency transition and polymerization in inhibitory serpins.

Authors:  Ji-Yeun Yi; Hana Im
Journal:  Protein Sci       Date:  2007-03-30       Impact factor: 6.725

7.  COX-1(+/-)COX-2(-/-) genotype in mice is associated with shortened time to carotid artery occlusion through increased PAI-1.

Authors:  T E Riehl; L He; L Zheng; S Greco; D M Tollefsen; W F Stenson
Journal:  J Thromb Haemost       Date:  2011-02       Impact factor: 5.824

8.  Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.

Authors:  Shih-Hon Li; Ashley A Reinke; Karen L Sanders; Cory D Emal; James C Whisstock; Jeanne A Stuckey; Daniel A Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

9.  Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation.

Authors:  Ola Fjellström; Johanna Deinum; Tove Sjögren; Carina Johansson; Stefan Geschwindner; Viveca Nerme; Anne Legnehed; Jane McPheat; Karolina Olsson; Cristian Bodin; Amalia Paunovic; David Gustafsson
Journal:  J Biol Chem       Date:  2012-11-15       Impact factor: 5.157

10.  Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.

Authors:  Shih-Hon Li; Natalia V Gorlatova; Daniel A Lawrence; Bradford S Schwartz
Journal:  J Biol Chem       Date:  2008-04-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.